The National Agency for Food and Drug Administration and Control (NAFDAC) has officially blacklisted Onifam Laboratories due to severe regulatory violations.

The agency accused the company of misusing approvals, failing to meet safety standards, and engaging in fraudulent practices that threaten public health.

This decision comes after a thorough investigation into the laboratory's operations, which revealed systemic issues in drug production and distribution.

As part of the sanctions, Onifam is barred from participating in any NAFDAC-regulated activities in Nigeria, including manufacturing, importing, or distributing pharmaceutical products.The blacklist will remain in effect until further notice, with NAFDAC reserving the right to pursue additional legal actions against the company.

This move underscores the agency's commitment to maintaining strict regulatory oversight in the healthcare sector and protecting consumers from substandard medical products.

Industry experts have praised the decision as a necessary step to uphold pharmaceutical integrity, though some argue it could impact access to certain medications.The case highlights the critical role of regulatory bodies in ensuring drug safety and the consequences for companies that disregard these standards.